{
    "root": "38bdc7bd-c714-452e-910a-c4afa36ef1f8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Qulipta",
    "value": "20250321",
    "ingredients": [
        {
            "name": "ATOGEPANT",
            "code": "7CRV8RR151",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_196955"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_78913"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00815"
        },
        {
            "name": "VITAMIN E POLYETHYLENE GLYCOL SUCCINATE",
            "code": "O03S90U1F2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_33234"
        }
    ],
    "indications": {
        "text": "qulipta indicated preventive treatment migraine adults .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "qulipta taken orally without food . ( 2.1 ) episodic migraine , recommended 10 mg , 30 mg , 60 mg taken daily . ( 2.1 ) chronic migraine , recommended 60 mg taken daily . ( 2.1 ) severe renal impairment end-stage renal disease ( 2.2 , 8.6 ) : episodic migraine : 10 mg daily . chronic migraine : avoid .",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "qulipta 10 mg supplied white off-white , round biconvex tablets debossed \u201c \u201d \u201c 10 \u201d one side following packaging presentations : bottle 30 , ndc : 0074-7095-30 qulipta 30 mg supplied white off-white , oval biconvex tablets debossed \u201c a30 \u201d one side following packaging presentations : bottle 30 , ndc : 0074-7096-30 qulipta 60 mg supplied white off-white , oval biconvex tablets debossed \u201c a60 \u201d one side following packaging presentations : bottle 30 , ndc : 0074-7094-30",
    "adverseReactions": "qulipta contraindicated patients history hypersensitivity atogepant components qulipta . included anaphylaxis dyspnea [ ( 5.1 ) ] .",
    "indications_original": "QULIPTA\u00a0is indicated for the preventive treatment of migraine in adults.",
    "contraindications_original": "QULIPTA is taken orally with or without food. ( 2.1 ) For episodic migraine, the recommended dosage is 10 mg, 30 mg,\u00a0or 60 mg taken once daily. ( 2.1 ) For chronic migraine, the recommended dosage is 60 mg taken once daily. ( 2.1 ) Severe Renal Impairment or End-Stage Renal Disease\u00a0( 2.2 , 8.6 ): Episodic migraine: 10 mg once daily. Chronic migraine: Avoid use.",
    "warningsAndPrecautions_original": "QULIPTA 10 mg\u00a0is\u00a0supplied as\u00a0white to off-white, round\u00a0biconvex tablets debossed with \u201cA\u201d and \u201c10\u201d\u00a0on one side in the following packaging presentations:\n                        \n                           Bottle of 30, NDC: 0074-7095-30\n                        \n                        QULIPTA 30 mg\u00a0is\u00a0supplied as\u00a0white to off-white, oval biconvex tablets debossed with \u201cA30\u201d on one side in the following packaging presentations:\n                        \n                           Bottle of 30, NDC: 0074-7096-30\n                        \n                        QULIPTA 60 mg\u00a0is\u00a0supplied as\u00a0white to off-white, oval biconvex tablets debossed with \u201cA60\u201d on one side in the following packaging presentations:\n                        \n                           Bottle of 30, NDC: 0074-7094-30",
    "adverseReactions_original": "QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA. Reactions have included anaphylaxis and dyspnea [see Warnings and Precautions (\n                     \n                        5.1\n                     \n                     )].",
    "drug": [
        {
            "name": "Qulipta",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_196955"
        }
    ]
}